CANNABIS INNOVATION, GENETICS & EXTRACTION INVESTOR BRIEF | JANUARY 2021 - EXKA
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
CANNABIS INNOVATION, GENETICS & EXTRACTION
INVESTOR BRIEF | JANUARY 2021
PRIVATE AND CONFIDENTIAL EXKA 2021 | Cannabis Innovation, Genetics & Extraction
BUILDING A
Hybrid Ancillary GMP Purpose-Built Plant Tissue Culture Laboratory
Greenhouses Facility Extraction Facility & Administrative Spaces
Ø 27,000 ft2 Ø 16,000 ft2 Ø 6,500 ft2 Ø 9,000 ft2
Ø Research and Development Ø Clone acclimatization Ø Capacity to extract 150,000 kg Ø Up to 2M cannabis clones per year
in Agricultural Sciences Ø Biomass prep for extraction of biomass/year Ø Clonal repository
Ø > 2,500 kg of cannabis Ø Shipping & Receiving Ø Capacity to produce 24,000 kg Ø Genetic fingerprinting
flowers/year Ø Electro-mechanical support of distillate/year Ø Laboratory currently in operation
Ø Commissioning: Q4/2020 Ø Commissioning: Q3/2020 Ø Commissioning: Q3/2020
Property
Mirabel, QC Canada
Ø 67 hectares
Ø Significant scalability with 126 cultivable acres
Ø Potential annual production of >100,000kg of cannabis biomass
Ø Commissioning: Q2/2021
PRIVATE AND CONFIDENTIAL | 1 EXKA 2021 | Cannabis Innovation, Genetics & Extraction
OUR VISION WHAT WE DO PRODUCTS
& SERVICES
EXKA is a cannabis research, development EXKA specializes in genetics and extraction
and innovation campus striving to be a leader of pharmaceutical grade cannabis oil. The
Plantlets
in cannabis innovation, genetics and extraction company supplies the life science
through unique scientific know-how. (pharmaceutical, OTC, animal health, research)
and the cannabis (licence holders, food)
markets.
Genetics
BUSINESS UNITS
Cannabis Genetics Cannabis Extraction Your Clone in the
Cloud TM
Ø Unique, Stable and Uniform Clones Ø Pharma-grade extraction service
Ø Genetic Fingerprinting Ø Value-added cannabis extracts Cannabis Oil
Ø Germplasm Audit
Ø Your Clone in the Cloud TM Genetic Storage
Ø Propagate your own varieties
Ø Propagate EXKA’s genetic library
PRIVATE AND CONFIDENTIAL | 2 EXKA 2021 | Cannabis Innovation, Genetics & Extraction
ABOUT CANNABIS PRIVATE AND CONFIDENTIAL | 3 EXKA 2021 | Cannabis Innovation, Genetics & Extraction
EXKA IN THE CANNABIS MARKET
Ø EXKA focuses on the highest margin segments of the cannabis market :
Ø Cannabis Genetics in a state-of-the-art cannabis plant tissue culture
laboratory with a genetic bank able to micropropagate a consistent
supply of novel and best in class strains for specific LPs needs.
Ø Cannabis Extraction on a R&D agricultural science platform creates an
evolving scientific expertise that leads to product differentiation in
“white label” specialty oil products.
Ø EXKA’s purpose-built facilities serves as a full circle cannabis innovation hub,
where most licence holders only produce flowers and very few have
extraction capabilities beyond “crude resin”.
PRIVATE AND CONFIDENTIAL | 4 EXKA 2021 | Cannabis Innovation, Genetics & Extraction
EXTRACTION FACILITY AT EXKA
IS GMP READY
CANNABIS MARKET IS EVOLVING
TOWARDS EXTRACTS
Ø The therapeutic Indications for chronic pain, neuropathic
pain, cancer-related pain and in palliative care, averages out
between 69 % and 79%. Source: CanniMed, IPO
Ø The market is now split 50% / 50% between smokables and
new novel form factors such as vape pens, edibles, beverages
and other innovative products. Source: GMP Securities
Ø Cannabis extract is a premium product, the more it is refined,
the higher its value. Source: SQDC website
Ø Cannabis oil :
C$23.46/g equivalent | Premium = 141%
Ø Cannabis soft-gel capsules :
C$72.68/g equivalent | Premium = 645%
PRIVATE AND CONFIDENTIAL | 5 EXKA 2021 | Cannabis Innovation, Genetics & Extraction
HEALTH CANADA CANNABIS LICENCES
EXKA holds a cannabis cultivation and processing licence and a cannabis analytical testing licence from Health
Canada. The Company recently submitted an amendment to the current cultivation and processing licence to
include extraction and greenhouses facilities and expects to have these facilities licenced in the near term, with
the expectation to have all of its facilities licenced by Q3/2020 (base case scenario). However, the team is
deploying all the efforts to outpace the licence change for Q2 2020 (best case scenario).
EXKA received its EXKA received its
cultivation and processing licence licence for analytical testing of cannabis
from Health Canada on February 28, 2020 : from Health Canada on January 24, 2020 :
Ø This licence allows EXKA to operate its Ø This licence allows EXKA to perform
plant tissue culture laboratory and cannabis testing in our laboratories.
offer micropropagation and genetic
storage services to licensed cannabis
producers.
PRIVATE AND CONFIDENTIAL | 6 EXKA 2021 | Cannabis Innovation, Genetics & Extraction
EXKA’S GENETICS & EXTRACTION SERVICES IN THE VALUE CHAIN
Ø EXKA is able to deliver predictable, reliable, resilient and robust quality plantlets for indoor/outdoor cultivation in
large volume at any given time.
Ø Our genetics in synergy with our extraction process leads to product differentiation in “white label” specialty oil extracts.
EXTRACTION
Novel
form factors
Start Stage I Stage II Stage III & IV Starting
Mother Establishment Shoot Multiplication Rooting & Material
Plant of explants and Genetic Storage Acclimatization
FLOWERS
- Explant - Genotyping Services Your Clone in the CloudTM - In vitro cultures - Plantlets Combustible
- R&D Projects - Ex vitro plants products
PRIVATE AND CONFIDENTIAL | 7 EXKA 2021 | Cannabis Innovation, Genetics & Extraction
ADVANTAGES OF MICROPROPAGATION
Ø Maintain genetic stability
Ø Rely on stable, uniform, vigorous, Specific Pathogen Tested (SPT), high quality
starting material for better yield and performance
Ø Reduce incidence of plant pathogens by using SPT starting material
Ø Reduce or eliminate mother room costs
Ø Improve yield
Ø Increase overall profitability by improving revenues and reducing costs
ABOUT THE PROCESS
Time (months) 0 1 2 3 4 5 6 7 8
Clones 1 5 25 625 3,125 15,625 78,125 390,625 1,953,125
PRIVATE AND CONFIDENTIAL | 8 EXKA 2021 | Cannabis Innovation, Genetics & Extraction
ADVANTAGES OF YOUR CLONE IN THE CLOUD TM
Ø EXKA offers genetic storage services by maintaining client varieties in its clonal repository.
Ø LP genetics are safeguarded and propagated into robust, true to type and disease-free plantlets.
Ø Clones are kept in perpetuity in aseptic, stable and environmentally-controlled conditions and
propagated on demand to fit production schedules.
Ø Genetic material kept off-site represents an insurance policy by insuring the preservation of
valuable varieties.
Ø Specific-pathogen testing (SPT) and viral elimination services.
Ø Genetic fingerprinting services.
Ø EXKA offers Germplasm audit services by bringing plants into flowering and documenting their
characteristics.
Ø Ability to consistently supply novel and best in class genetic strains for specific LPs needs.
PRIVATE AND CONFIDENTIAL | 9 EXKA 2021 | Cannabis Innovation, Genetics & ExtractionEXKA CANNABIS GENETIC PORTFOLIO
Ø EXKA’s cannabis genetic bank strives to consistently supply novel and best in class genetic strains for specific LPs needs.
Ø Our 2020 varieties catalogue features our top genetics with a detailed guide to each strain’s specific traits and growing
needs, this also includes pages of scientific advice to help LPs yield the best results out of their investment.
PRIVATE AND CONFIDENTIAL | 10 EXKA 2021 | Cannabis Innovation, Genetics & ExtractionØ GMP extraction facility ready for domestic and international markets.
EXTRACTION SERVICES Ø Precise and tailored extraction services that can provide the right concentration
of cannabinoids customized to our client’s desired “white label” format.
PRIMARY EXTRACTION SECONDARY PROCESSING
Sourcing Milling Extracting Winterizing Evaporating Distillation
Cannabis Grind Crude Extract Winterized Oil Crude Resin Distillate
Biomass consists Testing & Analysis Supercritical CO2 Wax & Lipids are Ethanol Precipitated Rotary Short Path Distillation
of dry flowers, removed Evaporation & & Terpene Fractions
trim & shake Decarboxylation
Cannabinoid Concentration Cannabinoid Concentration Cannabinoid Concentration
50% - 60% 75% - 80% 90% - 95%
Input: 150,000 kg/year Input: 21,000 kg/year Input: 30,000 kg / year
Output: 15,000 kg/year Output: 17,000 kg/year Output: 24,000 kg / year
ACTIVE PHARMACEUTICAL INGREDIENT
PRIVATE AND CONFIDENTIAL | 11 EXKA 2021 | Cannabis Innovation, Genetics & ExtractionIN SUMMARY
Ø EXKA cannabis plant tissue culture laboratory with micro-
propagation and genetic storage capability is a key differentiator
in the industry.
Ø Our R&D agricultural science platform will generate rigour,
stability, consistency and efficiency in the production of
pharmaceutical-grade products (plantlets and oil extracts).
Ø EXKA is able to consistently supply novel and best in class genetic
strains for specific LPs needs.
Ø EXKA is able to provide the right concentration of cannabinoids
customized to the desired “white label” format.
Ø EXKA has the ability to adapt to create and supply specific
products and/or services meeting unique customer requirements
(plantlets, genetics, oil) for domestic and international markets.
PRIVATE AND CONFIDENTIAL | 12 EXKA 2021 | Cannabis Innovation, Genetics & ExtractionCheck out our New Web Site to find out more about our
RESEARCH PARTNERS in our CANNABIS CAMPUS … WEB SITE
For all INVESTOR RELATIONS
and up to date details on Ø REVENUE PATHS
Ø SIGNED CONTRACTS and LOIs
Ø GROWTH PLANS
Ø FINANCIAL FORECASTS
PLEASE CONTACT US DIRECTLY :
Maxime Paris Sébastien Désormeau
President & CEO COO
514 974 0099 514 910 5845
PRIVATE AND CONFIDENTIAL | 13 EXKA 2021 | Cannabis Innovation, Genetics & ExtractionFUNDING HISTORY
Q1 / 2018 Q3 / 2018 Q3 / 2019 Q1 / 2020 2020
Seed Round Private Placement A Private Placement B Private Placement C
(Closed) (Closed) (Closed) (Open)
START
4.55 million shares 7.4 million shares 1.9 million shares 2 million shares OF IPO
at $0.20 / share at $1.50 / share at $2.50 / share at $3.00 / share PRODUCTION
Total equity : $910,000 Total equity : $11.0 million Total equity : $4.7 million Total equity : $6.0 million
Convertible debenture : $8 million
Total : $12.7 million
TOTAL CAPITAL RAISED CAPEX TABLE 2018 - 2020
Property $2,500,000
as of April 6, 2020
Construction $16,200,000
Common equity $16.7 M Vitalis Q-90 extractor $720,000
Convertible debenture $8.0 M Deutsche winterization $320,000
Equipment
Total $24.7 M VTA Short-path distillation $225,000
Shares outstanding 14.0 M Nexus Greenhouses (27, 000 ft2) $1,596,000
Total $21,561,000
PRIVATE AND CONFIDENTIAL | 14 EXKA 2021 | Cannabis Innovation, Genetics & ExtractionWe focus on excellence We strive to create and share We spare no effort to adapt to
in everything that we do knowledge and to better the budding cannabis industry
and aim at developing understand the science that will by developing materials and
products and services of lead to better quality products methods that are best suited to
outstanding quality. and services. this dynamic environment.
OUR VALUES
Maxime Paris Sébastien Désormeau
CONNECT max@exka.com sdesormeau@exka.com
514 974 0099 514 910 5845
DISCAIMER | This document and the information it contains is property of EXKA.
All the photography in this document is also licensed to EXKA by Photographer Karyn Dupuis. These images have been captured over the last ten months on
EXKA property for documentation and marketing purposes, they are an up-to-date portrait of our facilities and staff.
PRIVATE AND CONFIDENTIAL | 15 EXKA 2021 | Cannabis Innovation, Genetics & ExtractionYou can also read
